These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 10167344)

  • 21. Theory and methods of economic evaluation of health care.
    Johannesson M
    Dev Health Econ Public Policy; 1996; 4():1-245. PubMed ID: 10158916
    [No Abstract]   [Full Text] [Related]  

  • 22. The limits of cost-effectiveness analysis.
    Weintraub WS; Cohen DJ
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):55-8. PubMed ID: 20031813
    [No Abstract]   [Full Text] [Related]  

  • 23. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension.
    Johannesson M; Meltzer D; O'Conor RM
    Med Decis Making; 1997; 17(4):382-9. PubMed ID: 9343796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.
    Angus DC; Linde-Zwirble WT; Clermont G; Ball DE; Basson BR; Ely EW; Laterre PF; Vincent JL; Bernard G; van Hout B;
    Crit Care Med; 2003 Jan; 31(1):1-11. PubMed ID: 12544986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Costs, true costs, and whose costs in economic analyses in medicine?
    Macones GA; Asch DA
    Am J Manag Care; 1997 Jun; 3(6):915-7. PubMed ID: 10170295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health services research clinical trials: issues in the evaluation of economic costs and benefits.
    Manheim LM
    Control Clin Trials; 1998 Apr; 19(2):149-58. PubMed ID: 9551279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A note on the depreciation of the societal perspective in economic evaluation of health care.
    Johannesson M
    Health Policy; 1995 Jul; 33(1):59-66. PubMed ID: 10143700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.
    Neumann PJ; Cohen JT; Weinstein MC
    N Engl J Med; 2014 Aug; 371(9):796-7. PubMed ID: 25162885
    [No Abstract]   [Full Text] [Related]  

  • 29. Priorities and research strategy in health economics for the 1990s.
    Williams A
    Health Econ; 1993 Dec; 2(4):295-302. PubMed ID: 8142991
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of cost effectiveness analysis in health care evaluation.
    Atherly A; Culler SD; Becker ER
    Q J Nucl Med; 2000 Jun; 44(2):112-20. PubMed ID: 10967622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expenditures.
    Chambers JD; Lord J; Cohen JT; Neumann PJ; Buxton MJ
    Value Health; 2013 Jun; 16(4):629-38. PubMed ID: 23796298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative value in healthcare: cost-effectiveness of interventions.
    Siegel JE; Clancy CM
    J Nurs Care Qual; 2006; 21(2):99-103. PubMed ID: 16540774
    [No Abstract]   [Full Text] [Related]  

  • 33. Editorial comment--stroke cost-effectiveness research: are acceptability curves acceptable?
    Holloway R; Dick AW
    Stroke; 2004 Jan; 35(1):203-4. PubMed ID: 14684768
    [No Abstract]   [Full Text] [Related]  

  • 34. Accounting for the missing opportunity costs in incremental cost-outcome analysis.
    Oliver A
    Appl Health Econ Health Policy; 2002; 1(4):191-6. PubMed ID: 14619248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy.
    Hornberger J; Holodniy M; Robertus K; Winnike M; Gibson E; Verhulst E
    Med Decis Making; 2007; 27(6):789-821. PubMed ID: 18057191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The costs and benefits of enhanced depression care to employers.
    Wang PS; Patrick A; Avorn J; Azocar F; Ludman E; McCulloch J; Simon G; Kessler R
    Arch Gen Psychiatry; 2006 Dec; 63(12):1345-53. PubMed ID: 17146009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of hip protector use on a geriatric ward in Germany: a Markov model.
    Stollenwerk B; Bartmus T; Klug F; Stock S; Müller D
    Osteoporos Int; 2015 Apr; 26(4):1367-79. PubMed ID: 25572047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimating the Societal Benefits of THA After Accounting for Work Status and Productivity: A Markov Model Approach.
    Koenig L; Zhang Q; Austin MS; Demiralp B; Fehring TK; Feng C; Mather RC; Nguyen JT; Saavoss A; Springer BD; Yates AJ
    Clin Orthop Relat Res; 2016 Dec; 474(12):2645-2654. PubMed ID: 27699631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of practice-initiated quality improvement for depression: results of a randomized controlled trial.
    Schoenbaum M; Unützer J; Sherbourne C; Duan N; Rubenstein LV; Miranda J; Meredith LS; Carney MF; Wells K
    JAMA; 2001 Sep; 286(11):1325-30. PubMed ID: 11560537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip.
    Chang RW; Pellisier JM; Hazen GB
    JAMA; 1996 Mar; 275(11):858-65. PubMed ID: 8596224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.